Gene Therapy Candidate Granted Fast Track Designation for Treatment of Achromatopsia
The FDA has granted a fast track designation to gene therapy product candidate AAV-CNGB3 for the treatment of achromatopsia caused by mutations in the CNGB3 gene.
The US Food and Drug Administration (FDA) has granted a fast track designation to MeiraGTx Holdings Plc’s gene therapy product candidate—AAV-CNGB3—for the treatment of patients with achromatopsia caused by mutations in the CNGB3 gene.
Currently, no effective treatments are available to combat the disease.
“We are thrilled by this designation and the continued recognition by the FDA of AAV-CNGB’s potential to become a much-needed treatment option for achromatopsia patients suffering from this debilitating disease,” MeiraGTx’s president and chief executive officer Alexandria Forbes, PhD, said in a
MeiraGTx is currently in the process of conducting a
For the dose escalation phase of the trial, 18 adult participants will be given 1 of 3 different escalating doses of the therapy—a single low dose, a single medium dose, or a single high dose of range AAV-CNGB. After investigators are able to establish an acceptable dose in adult participants, they will then treat up to 9 children.
The primary outcome measure for the trial is the incidence of adverse events associated with the treatment, with safety defined as the absence of related safety events, while the secondary outcome measures include improvement of visual and retinal function and improvement in quality of life at 6 months.
To date, 14 patients have been treated; eleven adult patients have been treated with the therapy in the 3 dose escalation cohorts and 3 pediatric patients have received the treatment in the extension phase of the study. By the second half of 2018, MeiraGTx anticipates that they will complete dosing of up to 8 pediatric patients.
Additionally, investigators are also conducting an
Previously, the gene therapy has received an orphan drug designation from the FDA as well as an orphan medicinal product designation from the European Medicines Agency (EMA); furthermore, AAV-CNGB3 was also granted a rare pediatric disease designation by the FDA and PRIME designation by the EMA for treatment of patients with achromatopsia caused by mutations in the CNGB3 gene.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025